The Medical House, orthopaedic devices and drug delivery company and BioPartners GmbH the global biopharmaceuticals company are pleased to announce a 10 year agreement for license and supply of The Medical House's GH1 reusable, spring-powered, needle-free delivery system for the delivery of BioPartners’ human growth hormone product, Valtropin.
This deal follows from the development agreement between the companies which was signed in June 2002. The GH1 received CE mark regulatory approval in 2003.
The agreement is on an exclusive world-wide basis for an initial period of 10 years. Sales volumes of needle-free devices give The Medical House a projected income for the contract of £14 million, of which £3 million relates to the first five years. These figures exclude consumable items, such as nozzles and adaptors, which need to be replaced on a regular basis.
BioPartners has submitted an application for marketing authorisation (MA) to the European Medicines Evaluation Agency (EMEA) for Valtropin™. This is the second MA application submitted by BioPartners to the EMEA for a biosimilar product. The company submitted an application for its interferon alpha product last year, which is also currently being evaluated by the agency.
The two companies are also exploring the use of The Medical House’s new drug delivery systems, including the disposable AutoSafety Injector (ASI), with BioPartners’ sustained release formulations of biopharmaceuticals.
Commenting on the agreement, Jean-Noël Treilles, CEO, BioPartners GmbH, stated: